Sheng Yang

Prof. Sheng Yang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
HLHaiyu Liu
Haiyu Liu
NGNingjing Guo
Ningjing Guo
QZQixian Zheng
Qixian Zheng
QZQianyuan Zhang
Qianyuan Zhang
JCJinghan Chen
Jinghan Chen
SZSuyun Zhang
Suyun Zhang
Background: Coronavirus disease 2019 (COVID-19) is frequntly accompanied by venous thromboembolism (VTE), and its mechanism may be related to the abnormal inflammation and immune status of COVID-19 patients. It has been proved that interleukin-6 (IL-6), ferritin and lactate dehydrogenase (LDH) may play an important role in the occurrence of VTE in COVID-19 infection. But whether they can server as predictors for VTE in COVID-19 is still unclear. In this study, we performed a systematic review and meta-analysis to compare IL-6, ferritin and LDH in VTE and non-VTE COVID-19 patients in order to shed light on the prevention and treatment of VTE. Methods: Related literatures were searched in PubMed, Embase, Web of Science, Google Scholar, China National Knowledge Infrastructure (CNKI), WANGFANG. COVID-19 patients were divided into VTE group and non-VTE group. Meta-analysis was then conducted to compare levels of IL-6, ferritin and LDH between the two groups. Results: We finally included and analyzed 17 literatures from January 2019 to October 2022. There was a total of 7,035 COVID-19 patients, with a weighted mean age of 60.01 years. Males accounted for 62.64% and 61.34% patients were in intensive care unit (ICU). Weighted mean difference (WMD) of IL-6, ferritin and LDH was 31.15 (95% CI: 9.82, 52.49), 257.02 (95% CI: 51.70, 462.33) and 41.79 (95% CI: -19.38, 102.96), respectively. The above results indicated that than compared with non-VTE group, VTE group had significantly higher levels of IL-6 and ferritin but similar LDH. Conclusion: This systematic review and meta-analysis pointed out that elevated levels of IL-6 and ferritin were significantly possitive associated with VTE, thus could be used as biological predictive indicators of VTE among COVID-19 patients. However, no association was found between level of LDH and VTE. Therefore, close monitoring of changes in IL-6 and ferritin concentrations is of great value in assisting clinicans to rapidly identify thrombotic complications among COVID-19 patients, hence facilitating the timely effective managment. Further studies are required in terms of the clinical role of cytokines in the occurrence of VTE among COVID-19 infection, with more reliable systematic controls and interventional trials.

25 March 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NGNingjing Guo
Ningjing Guo
QLQiong Luo
Qiong Luo
QZQixian Zheng
Qixian Zheng
SYSheng Yang
Sheng Yang
SZSuyun Zhang
Suyun Zhang
ADP-dependent glucokinase (ADPGK) produces glucose-6-phosphate with adenosine diphosphate (ADP) as the phosphate group donor, in contrast to ATP-dependent hexokinases (HKs). Originally found in archaea, ADPGK is involved in glycolysis. However, its biological function in most eukaryotic organisms is still unclear, and the molecular mechanism of action requires further investigation. This paper provides a concise overview of ADPGK’s origin, biological function and clinical application. It aims to furnish scientific information for the diagnosis and treatment of human metabolic diseases, neurological disorders, and malignant tumours, and to suggest new strategies for the development of targeted drugs.

22 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SZSu-Yun Zhang
Su-Yun Zhang
QLQiong Luo
Qiong Luo
LXLi-Rong Xiao
Li-Rong Xiao
FYFan Yang
Fan Yang
JZJian Zhu
Jian Zhu
SYSheng Yang
Sheng Yang
Background: Gastric cancer (GC) is one of the major malignancies threatening human lives and health. Non-SMC condensin II complex subunit D3 (NCAPD3) plays a crucial role in the occurrence of many diseases. However, its role in GC remains unexplored.Materials and Methods: The Cancer Genome Atlas (TCGA) database, clinical samples, and cell lines were used to analyze NCAPD3 expression in GC. NCAPD3 was overexpressed and inhibited by lentiviral vectors and the CRISPR/Cas9 system, respectively. The biological functions of NCAPD3 were investigated in vitro and in vivo. Gene microarray, Gene set enrichment analysis (GSEA) and ingenuity pathway analysis (IPA) were performed to establish the potential mechanisms.Results: NCAPD3 was highly expressed in GC and was associated with a poor prognosis. NCAPD3 upregulation significantly promoted the malignant biological behaviors of gastric cancer cell, while NCAPD3 inhibition exerted a opposite effect. NCAPD3 loss can directly inhibit CCND1 and ESR1 expression to downregulate the expression of downstream targets CDK6 and IRS1 and inhibit the proliferation of gastric cancer cells. Moreover, NCAPD3 loss activates IRF7 and DDIT3 to regulate apoptosis in gastric cancer cells.Conclusion: Our study revealed that NCAPD3 silencing attenuates malignant phenotypes of GC and that it is a potential target for GC treatment.

5 April 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
XCXinwang Chen
Xinwang Chen
SZSuyun Zhang
Suyun Zhang
HLHaiyu Liu
Haiyu Liu
QZQianyuan Zhang
Qianyuan Zhang
JCJinghan Chen
Jinghan Chen
XCXiangqi Chen
Xiangqi Chen
Objective: Anticoagulation is crucial for patients hospitalized with coronavirus disease 2019 (COVID-19) due to the high risk of venous thromboembolism (VTE). However, the optimal anticoagulation regimen needs further exploration. Therefore, we evaluated the efficacy and safety of diverse anticoagulation dosage dosages for COVID-19.Methods: An updated meta-analysis was performed to assess the effect of thromboprophylaxis (standard, intermediate, and therapeutic dose) on the incidence of VTE, mortality and major bleeding among COVID-19 patients. Literature was searched via PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure (CNKI) database. The odds ratio (OR) and 95% confidence interval (CI) were calculated for effect estimates.Results: Nineteen studies involving 25,289 participants without VTE history were included. The mean age of patients was 59.3 years old. About 50.96% were admitted to the intensive care unit. In the pooled analysis, both therapeutic-dose and intermediate-dose anticoagulation did not have a significant advantage in reducing VTE risk over standard dosage (OR = 1.09, 95% CI: 0.58–2.02, and OR = 0.89, 95% CI: 0.70–1.12, respectively). Similarly, all-cause mortality was not further decreased in either therapeutic-dose group (OR = 1.12, 95% CI: 0.75–1.67) or intermediate-dose group (OR = 1.34, 95% CI: 0.83–2.17). While the major bleeding risk was significantly elevated in the therapeutic-dose group (OR = 2.59, 95%CI: 1.87–3.57) as compared with the standard-dose regimen. Compared with intermediate dosage, therapeutic anticoagulation did not reduce consequent VTE risk (OR = 0.85, 95% CI: 0.52–1.38) and all-cause mortality (OR = 0.84, 95% CI: 0.60–1.17), but significantly increased major bleeding rate (OR = 2.42, 95% CI: 1.58–3.70). In subgroup analysis of patients older than 65 years, therapeutic anticoagulation significantly lowered the incidence of VTE in comparation comparison with standard thromboprophylaxis, however, at the cost of elevated risk of major bleeding.Conclusion: Our results indicated that for most hospitalized patients with COVID-19, standard-dose prophylactic anticoagulation might be the optimal choice. For elderly patients at low risk of bleeding, therapeutic-dose anticoagulation could further reduce VTE risk and should be considered especially when there were other strong risk factors of VTE during hospital stay.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier, CRD42023388429.

11 December 2025 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
QLQiong Luo
Qiong Luo
HLHaiyu Liu
Haiyu Liu
QZQixian Zheng
Qixian Zheng
QZQianyuan Zhang
Qianyuan Zhang
SZSuyun Zhang
Suyun Zhang
SYSheng Yang
Sheng Yang
Objective: This study aims to evaluate the prevalence of anxiety and depression in patients with novel coronavirus pneumonia (COVID-19), with and without tumors, and to identify associated factors for improving therapy and quality of life. Methods: Seventy-four patients diagnosed with COVID-19 were form Fujian Medical University Affiliated Union Hospital from Fujian Medical University Affiliated Union Hospital were enrolled. The Hospital Anxiety and Depression Scale, Medical Coping Modes Questionnaire, Social Support Rating Scale, Type D Personality Scale, and neutrophil-to-lymphocyte ratio (NLR) were used to compare psychological status between tumor and non-tumor groups and to analyze related factors. Results: Among 74 patients, those with tumors ( n = 14) showed a higher prevalence of anxiety and depression than those without tumors (64.29% vs. 33.33%, p < 0.05). Social support scores and NLR differed significantly between the two groups ( p < 0.05), whereas coping styles and type D personality did not ( p > 0.05). Conclusion: COVID-19 patients with tumors exhibit higher rates of anxiety and depression, affected by social support and NLR. These findings emphasize the need for early multidisciplinary interventions integrating psychological and immunological assessment.